TQA 3605
Alternative Names: TQA-3605Latest Information Update: 03 Jan 2024
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antivirals; Small molecules
- Mechanism of Action Capsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Hepatitis B
Most Recent Events
- 27 Nov 2023 Phase-I/II clinical trials in Hepatitis B (Monotherapy, Treatment-experienced) in China (PO) (NCT06150014)
- 27 Nov 2023 Phase-I/II clinical trials in Hepatitis B (Monotherapy, Treatment-naive) in China (PO) (NCT06150014)
- 27 Nov 2023 Phase-I/II clinical trials in Hepatitis B (Treatment-experienced, Combination therapy) in China (PO) (NCT06150014)